Form 4: Mersana Director Sells All Holdings Post-Merger

Andrew Hack, a director of Mersana Therapeutics, Inc., disposed of all his direct and indirect common stock and stock options following the company's merger with Day One Biopharmaceuticals, Inc.

Summary

• Andrew Hack, a director of Mersana Therapeutics, Inc., reported the disposition of all his beneficial ownership in the company.
• This transaction occurred on January 6, 2026, following the effective merger of Mersana Therapeutics with Emerald Merger Sub, Inc., a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.
• Hack directly disposed of 578 shares of common stock.
• He indirectly disposed of 346,545 shares of common stock held by Bain Capital Life Sciences Entities.
• All outstanding stock options were also disposed of.
• Common stock shares were exchanged for $25.00 per share in upfront cash and one non-tradeable contingent value right (CVR) per share, potentially worth up to an additional $30.25 per CVR.
• Cash-Out Options (exercise price less than $25.00) were converted into the Offer Price minus the exercise price.
• Out-of-the-Money (OTM) Options (exercise price equal to or greater than $25.00) were cancelled if not exercised by the Last Exercise Date, receiving no consideration.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, which typically provides a clear exit for shareholders at a defined value, including potential upside from CVRs. While Out-of-the-Money options were cancelled without consideration if not exercised, the overall event represents a structured corporate action with defined outcomes.

Positives

• Shareholders received an upfront cash consideration of $25.00 per share as part of the merger.
• Shareholders also received a contingent value right (CVR) potentially worth up to $30.25 per CVR, offering future upside based on milestone achievements.
• Cash-Out Options (options with an exercise price less than the upfront cash consideration) were converted into cash, providing value to option holders.

Negatives

• Out-of-the-Money (OTM) options with exercise prices equal to or greater than $25.00 were cancelled if not exercised by the specified deadline, resulting in no consideration for those holders.
• The contingent value rights (CVRs) are non-tradeable, which limits liquidity for the contingent value component of the merger consideration.

Risks

• The value of the contingent value rights (CVRs) is dependent on the achievement of specified milestones, meaning the full potential payment of $30.25 per CVR is not guaranteed.
• Holders of Out-of-the-Money (OTM) options faced the risk of losing their options if they were not exercised by the Last Exercise Date prior to the merger's effective time.

Future Outlook

The filing indicates the completion of the merger, with Mersana Therapeutics, Inc. becoming a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. The future outlook for former Mersana shareholders now depends on the achievement of milestones tied to the contingent value rights.

Management Comments

• "Pursuant to the terms of that certain Agreement and Plan of Merger... the shares... were exchanged for: (i) $25.00 per Share, net to the stockholder in cash... plus (ii) one non-tradeable contingent value right per Share..."
• "After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026... with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."

Industry Context

This transaction represents a consolidation in the biotechnology or pharmaceutical sector, where larger companies often acquire smaller, innovative firms to expand their pipeline or technology. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech mergers and acquisitions to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech mergers is a standard practice, often seen in deals where the acquired company has pipeline assets with uncertain future value. Similar structures have been observed in acquisitions such as Celgene's acquisition of Receptos and Sanofi's acquisition of Principia Biopharma.
• The combination of an upfront cash component with CVRs aligns with common deal structures in the industry, aiming to balance immediate returns for shareholders with potential future upside tied to asset performance.

Corporate Governance

Related Party Transactions

• Andrew Hack's indirect beneficial ownership through Bain Capital Life Sciences Entities highlights a related party relationship, where Bain Capital, a significant investor, was involved in the disposition of shares as part of the merger.

Stakeholder Impact

• Shareholders: Received upfront cash and contingent value rights (CVRs) for their shares, providing a defined exit value and potential future payments.
• Option Holders: Those with 'Cash-Out Options' received cash value; those with 'Out-of-the-Money Options' faced a deadline to exercise or lose their options.
• Day One Biopharmaceuticals: Acquired Mersana, expanding its assets and potentially its market position.

Next Steps

• Monitoring the achievement of specified milestones for the contingent value rights to determine the realization of additional payments.

Key Dates

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Merger, SEC Form 4, Beneficial Ownership, Stock Options, Contingent Value Rights, MRSN, Acquisition, Insider Transaction